课题基金 / 基金详情

OSTEOPOROSIS TREATMENT IN THE NURSING HOME: NGRC TRIAL

OSTEOPOROSIS TREATMENT IN THE NURSING HOME: NGRC TRIAL
疗养院骨质疏松症治疗:NGRC 试验
批准号:
6232365
负责人:
William B. Ershler
金额:
$7.98万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-09-30 至 2001-08-31

项目摘要

项目成果

William B. Ershler的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Taken from the application): Osteoporosis is a major cause of morbidity and mortality in the United States. It is a disease of aging and its prevalence increases with each decade of life. In the typical nursing home, well over half of the residents will have remarkably diminished bone density and most of these individuals are susceptible to fractures. Optimal therapy has not been established. The current proposal is a clinical trial planning grant. Fourteen medical school affiliated nursing homes have organized into a research cooperative (The National Geriatrics Research Consortium [NGRC]) for the purpose of strengthening clinical research in the nursing home. This consortium plans to investigate a newly developed pharmacologic agent, zoledronate, for the treatment of osteoporosis in nursing home patients. In a one year planning phase, issues of research methodology and clinical trial design will be examined and a coordinated research proposal will be submitted upon completion of this planning phase. Several features about nursing home research make such a planning period advantageous. These include the likelihood of coexisting medical conditions in the patient volunteers and the frequent use of multiple other prescription medications. Furthermore, issues of informed consent from patients with cognitive impairment (as is the case with many, if not most of the potential subjects in our proposed trial), need to be fully understood. Details of the proposed trial are under development but it is the current expectation that it will be a multi institutional (NGRC), masked, randomized, placebo controlled clinical study in which nursing home patients with osteoporosis will receive either zoledronate or placebo every two months for two years. The primary outcome to be measured will be the occurrence of fractures and secondary outcomes will be pain relief, quality of life and bone mineral density. The outcome of this planning grant will be well constructed research proposal describing in detail this proposed clinical research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
2004 Conference on Advancing Cancer Care in Elderly
  • 批准号:
    6887970
  • 项目类别:
  • 资助金额:
    $0.75万
  • 财政年份:
    2005
  • 负责人:
    William B. Ershler
  • 依托单位:
SECOND INTERNATIONAL CONFERENCE ON IMMUNOLOGY AND AGING
INTERLEUKIN 6 AND OSTEOPOROSIS
  • 批准号:
    2330205
  • 项目类别:
  • 资助金额:
    $5.51万
  • 财政年份:
    1996
  • 负责人:
    William B. Ershler
  • 依托单位:
INTERLEUKIN 6 AND OSTEOPOROSIS
  • 批准号:
    2053292
  • 项目类别:
  • 资助金额:
    $33.56万
  • 财政年份:
    1995
  • 负责人:
    William B. Ershler
  • 依托单位:
海外基金